by Richard Daverman, PhD
November 7, 2013 -- Shanghai Sundise TCM Co. announced results from a US Phase II double-blinded, placebo-controlled clinical trial of a TCM product, Fuzheng Huayu tablet (FZHY). FZHY is used to treat liver fibrosis, and it was tested in chronic hepatitis C patients who have moderate to severe fibrosis. The drug was safe, well-tolerated and tended to stabilize or improve liver fibrosis, according to Sundise. To date, specific data from the trial has not been released. More details....
Help employers find you! Check out all the jobs and post your resume.
